Natus Medical Adds to Its Neurodiagnostic Service Market

• Acquires NeuroQuest, a Provider of Neurodiagnostic Services

PLEASANTON, Calif., March 03, 2016 -- Natus Medical Incorporated (NASDAQ:BABY) today announced that it has expanded its neurodiagnostic services into seven new states with the acquisition of the assets of NeuroQuest, LLC, a provider of neurodiagnostic services.

"The addition of NeuroQuest further strengthens our Global Neurodiagnostic ("GND") brand as a leading provider in our rapidly growing ambulatory EEG service business," said Jim Hawkins, President and Chief Executive Officer. "GND's organic growth combined with this acquisition offer an exciting opportunity for Natus and our customers as we expand the service throughout the United States." Hawkins continued.

"We expect this acquisition to add approximately $2.5 million in additional revenue during 2016 and to be immediately accretive to earnings," said Hawkins.

GND offers patients and physicians a more convenient way to complete ambulatory video EEG testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician.

About Natus Medical

Natus is a leading provider of healthcare products and services used in the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.

Additional information about Natus Medical can be found at www.natus.com.

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding historical revenue and profitability of GND the anticipated expansion of the GND services. These statements relate to current estimates and assumptions of our management as of the date of this press release, and future events or Natus' future financial performance or results, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, risks associated with bringing new products to market and integrating acquired businesses, and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2015, and its subsequent quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

COMPANY CONTACT: 
Natus Medical Incorporated 
Jonathan A. Kennedy
Sr. Vice President Finance and Chief Financial Officer 
(925) 223-6700
[email protected]